We are live on ! Find out more
RLAY icon

Relay Therapeutics

178 hedge funds and large institutions have $827M invested in Relay Therapeutics in 2024 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 75 increasing their positions, 49 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

53% more repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 49

5.36% less ownership

Funds ownership: 100.86%95.5% (-5.4%)

6% less funds holding

Funds holding: 189178 (-11)

25% less capital invested

Capital invested by funds: $1.1B → $827M (-$272M)

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

29% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 31

90% less call options, than puts

Call options by funds: $12K | Put options by funds: $117K

Holders
178
Holders Change
-11
Holders Change %
-5.82%
% of All Funds
2.57%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.04%
New
22
Increased
75
Reduced
49
Closed
31
Calls
$12K
Puts
$117K
Net Calls
-$105K
Net Calls Change
-$68K

RLAY Hedge Fund Activity: Q2 2024 in Review

178 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Relay Therapeutics (RLAY) for Q2 2024, worth a combined $827M — down 25% from $1.1B a quarter earlier.

Sellers outnumbered buyers: 31 funds closed out of RLAY and 22 opened new positions — a net loss of 9 holders — while 49 trimmed existing stakes and 75 added.

The largest buyer was Logos Global Management, opening a new position worth an estimated $8.88M. The largest seller was ArrowMark Colorado Holdings, cutting an estimated $23.7M.

  • 178 institutional investors held Relay Therapeutics (RLAY) as of Q2 2024, down from 189 in Q1 2024.
  • Funds reported $827M of Relay Therapeutics stock for Q2 2024, down 25% quarter-over-quarter.
  • 22 funds opened new Relay Therapeutics positions in Q2 2024 and 31 closed out, a net change of -9 holders.
  • The largest Relay Therapeutics buyer in Q2 2024 was Logos Global Management, an estimated $8.88M added.
  • The largest Relay Therapeutics seller in Q2 2024 was ArrowMark Colorado Holdings, an estimated $23.7M sold.

Based on aggregated 13F filings for Q2 2024.